

Clinical target volume definition in radiotherapy

Dates: 15.03.2026 - 18.03.2026

Venue: Monte Verita, Ascona, Switzerland

Program

Sunday 15.03.2025

18:00 Welcome reception

19:00 Dinner

Monday 16.03.2025

Nodal CTV definition

07:30-09:00 Breakfast

09:00-09:15 Introduction to Monte Verita (local staff)

09:15-09:30 Introduction to the workshop (Jan Unkelbach)

09:30-09:45 Introduction round (all participants)

09:45-12:30 **Elective CTV-N for HNSCC**

10:30-11:00 Coffee break

Current guidelines on ENI and ongoing trials on volume-deescalation
(Vincent Grégoire ~15 min)

Personalized estimation of risk of occult metastases
- Datasets on lymph node involvement and LyProx.org
- Statistical model of lymphatic progression
- DeEscO trial on personalized ENI for oropharyngeal SCC
(Jan Unkelbach)

Additional pitches:

Yoel Pérez Haas: Lymphatic progression model across all subsites

Noemi Bühner: Contralateral involvement depending on midline extension

Florian Putz: Atlas of LN metastases distribution

Andrew Hope: RADCURE dataset, EVADER trial, work at PMH

12:30-14:00 Lunch

14:00-15:30 **Elective CTV-N in breast cancer**

Current status and clinical evidence for ENI
(Paula Tsoutsou, ~15 min)

Personalized estimation of risk of occult metastases
- Datasets on lymph node involvement in breast cancer
- Statistical model of lymphatic progression applied to breast cancer
(group from Brussels)

15:30-16:00 Coffee break

16:00-17:00 **Elective CTV-N in lung cancer**

Less is more - the PET-Plan study
(Ursula Nestle)

17:00-18:00 **Elective CTV-N in prostate cancer**

Current status and controversy around ENI
(Thomas Zilli, ~15 min)

Initial thoughts on personalizing occult metastases risk
(group from Zürich, ~15min)

19:00 Dinner

Tuesday 17.03.2025

Primary tumor CTV definition

07:30-09:00 Breakfast

09:00-12:00 **The CTV in prostate cancer**

10:30-11:00 Coffee break

Blips and fizzles - The primary CTV in prostate cancer
(Uulke van der Heide)

Pitches:

Florian Putz: Atlas of LN metastases distribution

Simon Spohn: TBD

Marcel von Herk: TBD

Joint discussion on primary and nodal CTV

- possible collaborations
- datasets on pelvic lymph node involvement
- primary versus recurrent situation
- primary tumor characteristics relevant for metastatic spread

12:00-13:30 Lunch

13:30-14:15 **Primary tumor CTV in HNSCC**

The planned DAHANCA trial on reduced CTV margins
(Christian Ronn Hansen, ~15 min)

14:15-15:00 **Primary tumor CTV delineation in lung cancer**

Fitting models of subclinical disease spread to outcome data
(Marcel van Herk, ~15 min)

15:00-15:30 Coffee break

15:30-17:30 **CTV definition for Glioma**

Patterns of failure and clinical evidence for CTV definition
(Florian Putz, Simon Spohn ~15 min)

Glioma growth models for CTV definition

- Automated GTV-to-CTV expansion accounting for anatomical barriers
- Anisotropic spread in white matter
- Automated segmentation of relevant structures
(groups from Boston, Stockholm, Aarhus, Erlangen)

19:00 Dinner

Wednesday 18.03.2025

07:30-09:00 Breakfast

09:00-10:30 Dose prescription and probabilistic planning for the CTV

Elective dose de-escalation
Dose painting in the CTV
Handling uncertainty in CTV extension
TCP models for microscopic disease

Pitches:

Uulke van der Heide: The ICRU initiative on probabilistic planning
Marcel van Herk: Scenario based probabilistic planning for the CTV
Jan Unkelbach: TCP model for ENI for HNSCC
Thomas Bortfeld: TBD

10:30-11:00 Coffee break

11:00-12:30 Collaborations and funding opportunities

EU funding schemes
Bilateral collaborations
Potential white paper

12:30-14:00 Lunch

14:00-15:00 Wrap-up discussion

Participants

Jan Unkelbach, University Hospital Zürich, Switzerland
Vincent Grégoire, Centre Léon Bérard, Lyon, France
Thomas Bortfeld, Massachusetts General Hospital, Boston, MA
Jennifer Dhont, Université Libre De Bruxelles, Belgium
Stine Korreman, Aarhus University, Denmark
Iuliana Toma-Dasu, Stockholm University, Sweden
Marcel van Herk, University of Manchester, UK
Uulke van der Heide, Netherlands Cancer Institute, Amsterdam, Netherlands
Ursula Nestle, Kliniken Maria Hilf, Mönchengladbach, Germany
Panagiotis Balermipas, University Hospital Zürich, Switzerland
Jesper Kallehauge, Aarhus University, Denmark
Nick Reynaert, Université Libre De Bruxelles, Belgium
Yoel Pérez-Haas, University Hospital Zürich, Switzerland
Zineb Smine, Université Libre De Bruxelles, Belgium
Noemi Bühner, University Hospital Zürich, Switzerland
Lena Kretzschmar, University Hospital Zürich, Switzerland
Ali Alkhiat, Stockholm University, Sweden
Mehdi Astaraki, Stockholm University, Sweden
Adelina Brezae, Centre Léon Bérard, Lyon, France
Nadine Vatterodt, Paul Scherrer Institute, Switzerland
Florian Putz, Universitätsklinikum Erlangen, Germany
Simon Spohn, University Hospital Freiburg, Germany
Paula Tsoutsou, University Hospital Geneva, Switzerland
Thomas Zilli, Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
Letizia Deantonio, Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
Victor Strijbis, Inselspital Bern, Switzerland
Andrew Hope, Princess Margret Hospital, Toronto, Canada
Christian Ronn Hansen, Odense Hospital, Denmark
Maria Antonietta Piliero, Istituto Oncologico della Svizzera Italiana, Bellinzona
Marta Lazzeroni, Stockholm University, Sweden